Publications by authors named "Matthew W Martin"

Claim this Profile
N
Novel HDAC11 inhibitors suppress lung adenocarcinoma stem cell self-renewal and overcome drug resistance by suppressing Sox2.
Namrata Bora-Singhal, Durairaj Mohankumar, Biswarup Saha, Christelle M Colin, Jennifer Y Lee, Matthew W Martin

Sci Rep· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms.
Lanzhu Yue, Vasundhara Sharma, Nathan P Horvat, Afua A Akuffo, Matthew S Beatty, Matthew W Martin

Blood· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and optimization of novel piperazines as potent inhibitors of fatty acid synthase (FASN).
Matthew W Martin, David R Lancia, Hongbin Li, Shawn E R Schiller, Angela V Toms

Bioorg Med Chem Lett· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of novel N-hydroxy-2-arylisoindoline-4-carboxamides as potent and selective inhibitors of HDAC11.
Matthew W Martin, Jennifer Y Lee, David R Lancia, Pui Yee Ng, Bingsong Han

Bioorg Med Chem Lett· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and Optimization of Benzopiperazines as Potent Inhibitors of BET Bromodomains.
David S Millan, Katherine J Kayser-Bricker, Matthew W Martin, Adam C Talbot, Shawn E R Schiller

ACS Med Chem Lett· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Purinylpyridinylamino-based DFG-in/αC-helix-out B-Raf inhibitors: Applying mutant versus wild-type B-Raf selectivity indices for compound profiling" [Bioorg. Med. Chem. 24 (2016) 2215-2234].
Longbin Liu, Matthew R Lee, Joseph L Kim, Douglas A Whittington, Howard Bregman, Matthew W Martin

Bioorg Med Chem· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Purinylpyridinylamino-based DFG-in/αC-helix-out B-Raf inhibitors: Applying mutant versus wild-type B-Raf selectivity indices for compound profiling.
Longbin Liu, Matthew R Lee, Joseph L Kim, Douglas A Whittington, Howard Bregman, Matthew W Martin

Bioorg Med Chem· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Echo rounds: Transesophageal echocardiography: identification and management of a misplaced pedicle screw in the descending thoracic aorta after posterior spinal fusion.
Manoj H Iyer, Milo Engoren, Matthew W Martin

Anesth Analg· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-Based Design of Potent and Selective CK1γ Inhibitors.
Hongbing Huang, Lisa Acquaviva, Virginia Berry, Howard Bregman, Nagasree Chakka, Matthew W Martin

ACS Med Chem Lett· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2-Phenylamino-6-cyano-1H-benzimidazole-based isoform selective casein kinase 1 gamma (CK1γ) inhibitors.
Zihao Hua, Xin Huang, Howard Bregman, Nagasree Chakka, Erin F DiMauro, Matthew W Martin

Bioorg Med Chem Lett· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiothoracic anesthesiology fellowship: challenges of training and a novel approach to resident education.
Matthew W Martin, Jennifer L Vance, Thomas J Didier

J Cardiothorac Vasc Anesth· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Update on lymphocyte specific kinase inhibitors: a patent survey.
Matthew W Martin, Michelle R Machacek

Expert Opin Ther Pat· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of alpha-amidosulfones as potent and selective agonists of CB2: synthesis, SAR, and pharmacokinetic properties.
Isaac E Marx, Erin F DiMauro, Alan Cheng, Renee Emkey, Stephen A Hitchcock, Matthew W Martin

Bioorg Med Chem Lett· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structural modifications of N-arylamide oxadiazoles: Identification of N-arylpiperidine oxadiazoles as potent and selective agonists of CB2.
Erin F DiMauro, John L Buchanan, Alan Cheng, Renee Emkey, Stephen A Hitchcock, Matthew W Martin

Bioorg Med Chem Lett· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and optimization of a novel series of N-arylamide oxadiazoles as potent, highly selective and orally bioavailable cannabinoid receptor 2 (CB2) agonists.
Yuan Cheng, Brian K Albrecht, James Brown, John L Buchanan, William H Buckner, Matthew W Martin

J Med Chem· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity.
Matthew W Martin, John Newcomb, Joseph J Nunes, Christina Boucher, Lilly Chai

J Med Chem· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel 2,3-dihydro-1,4-benzoxazines as potent and orally bioavailable inhibitors of tumor-driven angiogenesis.
Daniel S La, Julie Belzile, James V Bready, Angela Coxon, Thomas DeMelfi, Matthew W Martin

J Med Chem· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation.
Erin F DiMauro, John Newcomb, Joseph J Nunes, Jean E Bemis, Christina Boucher, Matthew W Martin

J Med Chem· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.
Jean-Christophe Harmange, Matthew M Weiss, Julie Germain, Anthony J Polverino, George Borg, Matthew W Martin

J Med Chem· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of novel 2,3-diarylfuro[2,3-b]pyridin-4-amines as potent and selective inhibitors of Lck: synthesis, SAR, and pharmacokinetic properties.
Matthew W Martin, John Newcomb, Joseph J Nunes, Jean E Bemis, David C McGowan

Bioorg Med Chem Lett· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 4-amino-5,6-biaryl-furo[2,3-d]pyrimidines as inhibitors of Lck: development of an expedient and divergent synthetic route and preliminary SAR.
Erin F DiMauro, John Newcomb, Joseph J Nunes, Jean E Bemis, Christina Boucher, Matthew W Martin

Bioorg Med Chem Lett· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity.
Erin F DiMauro, John Newcomb, Joseph J Nunes, Jean E Bemis, Christina Boucher, Matthew W Martin

J Med Chem· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel 2-aminopyrimidine carbamates as potent and orally active inhibitors of Lck: synthesis, SAR, and in vivo antiinflammatory activity.
Matthew W Martin, John Newcomb, Joseph J Nunes, David C McGowan, David M Armistead

J Med Chem· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis